Research Programs
Moody Lab Portfolio
The Vaccine and Immunology Center for Influenza (VICI) consists of two influenza research programs.
Collaborative Influenza Vaccine Innovation Centers Contract
CIVICs aims to improve seasonal influenza vaccines and develop a universal vaccine.
The CIVIC program is funded by the National Institute of Allergic and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). It promotes multidisciplinary collaboration across institutions and industries from vaccine design and discovery, to good manufacturing practice (GMP) production and toxicology testing, to clinical trials and human challenge studies. Dr. Moody is the Principal investigator for the Duke CIVICs Vaccine Center (DCVC).
The DCVC has assembled a multi-disciplinary team to solve critical problems facing flu vaccine design and development.
COLLABORATORS
Dr. Steve Harrison at Boston Children’s Hospital,
Dr. Garnett Kelsoe, Dr. Masayuki Kuraoka, & Dr. Greg Sempowski at Duke University,
Dr. Aaron Schmidt at the Ragon Institute
Dr. Jiwon Lee at Dartmouth College
Influenza P01 Grant
Influenza remains a persistent global health threat that requires surveillance of circulating strains
This NIH-funded grant seeks to examine the updating of imprinted responses to influenza infection and vaccination that occurs during subsequent influenza vaccination. The hypothesis is that imprinting of B cell memory to influenza by initial infection has a greater effect on subsequent responses than does initial imprinting by influenza vaccine. These hypotheses are being tested in a series of experiments in humans and non-human primates (rhesus macaques) where we will probe the B cell repertoires in response to combinations of influenza infection and vaccination.
U19 Grant
Syphilis is a sexually transmitted infection caused by Treponema pallidum that remains a significant public health threat.
Despite effective testing and treatment algorithms, the rate of syphilis infections is increasing in the US, especially among economically disadvantaged persons. Development of a vaccine will speed elimination of this disease and reduce the burden of syphilis complications including congenital disease.
The goal of this program is to develop syphilis vaccine candidates.
This project is designed to characterize the immunological factors associated with protection. This project will isolate, characterize, and test monoclonal antibodies against syphilis derived from clinical samples obtained by our collaborators as well as antibodies that are developed in vitro using phage display techniques. The outcome of this work will be a new set of vaccine candidates that can be advanced to clinical trials.
The CREID Network seeks to create scalable global partnerships to address critical research topics, knowledge gaps, and disease outbreaks around the world.
Dr. Moody is co-Principal Investigator of the CREID Coordinating Center, alongside Dr. Don Brambilla of RTI. The Coordinating Center’s role is to provide administrative services, grow relationships with collaborators, establish new partnerships, and facilitate communication and operations during an outbreak response.
